47
Participants
Start Date
May 26, 2022
Primary Completion Date
January 28, 2025
Study Completion Date
January 28, 2025
V117957
V117957 1 mg - 1 tablet taken orally at bedtime.
Placebo
Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Manhattan Medical Research Practice, New York
AccuMed Research Associates, Garden City
MidLantic Urology, Bala-Cynwyd
Chesapeake Urology Research Associates, Owings Mills
Unified Women's Clinical Research-Lyndhurst Clinical Research, Winston-Salem
Accel Research Site - Neurostudies, Decatur
Accel Research Sites, DeLand
Urology Centers of Alabama, PC, Homewood
Otrimed Clinical Research, Edgewood
MetroHealth System, Cleveland
Revive Research Institute, Inc, Dearborn Heights
CentraCare - Urology Clinic, Sartell
Providea Health Partners LLC, Evergreen Park
Adult & Pediatric Urology P.C., Omaha
Southern Clinical Research Associates, Metairie
Ochsner Louisiana State University Health Shreveport - Regional University, Shreveport
Applied Research Center of Arkansas, Little Rock
Urological Associates of Southern Arizona, Tucson
Urology Group of Southern California, Los Angeles
Hope Clinical Research, LLC, Los Angeles
Investigational Site, Escondido
Tri Valley Urology Medical Group, Murrieta
Boston Clinical Trials, Boston
Bay State Clinical Trials, Inc., Watertown
Lead Sponsor
Purdue Pharma LP
INDUSTRY
Imbrium Therapeutics
INDUSTRY